StreetInsider.com News Articles

Regeneron extends BARDA Ebola treatment supply deal for $270M

Mon, 26 Oct 2026 07:02:38 -0400

Regeneron Pharmaceuticals (NASDAQ: REGN) has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of its Ebola treatment Inmazeb through 2031, with expected payment of approximately $270 million, according to a company statement.

The extension builds on an original procurement agreement signed in 2020. Under the updated terms, Regeneron will deliver additional doses of Inmazeb, a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn, to the U.S. government for Ebola preparedness purposes.

Inmazeb was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated for infection caused by Orthoebolavirus zairense in adult and

Regeneron extends BARDA Ebola treatment supply deal for $270M

Mon, 26 Oct 2026 07:02:38 -0400

Inmazeb was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated for infection caused by Orthoebolavirus zairense in adult and

Regeneron extends BARDA Ebola treatment supply deal for $270M

Mon, 26 Oct 2026 07:02:38 -0400

Inmazeb was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated for infection caused by Orthoebolavirus zairense in adult and

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Mon, 26 Oct 2026 07:00:00 -0400

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million

TARRYTOWN, N.Y., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to provide additional supply of Inmazeb^® (a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn) for U.S. preparedness against Ebola disease. Inmazeb was the first Ebola

Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness

Mon, 26 Oct 2026 07:00:00 -0400

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 million

Libtayo shows 37% death risk reduction in skin cancer trial

Mon, 26 Oct 2026 06:04:08 -0400

Regeneron Pharmaceuticals (NASDAQ: REGN) reported longer-term data from its Phase 3 C-POST trial showing an increasing overall survival benefit for cemiplimab, sold as Libtayo, as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma (CSCC). The data were presented at the European Society for Medical Oncology Congress 2026.

With a median follow-up of 44 months, the trial showed a 37% reduction in the risk of death for patients treated with Libtayo compared to placebo (hazard ratio: 0.63; 95% CI: 0.36-1.11). This compares to a 22% risk reduction at 30 months of follow-up and 14% at 24 months. The result is notable

Libtayo shows 37% death risk reduction in skin cancer trial

Mon, 26 Oct 2026 06:04:08 -0400

Libtayo shows 37% death risk reduction in skin cancer trial

Mon, 26 Oct 2026 06:04:08 -0400

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Sun, 25 Oct 2026 05:15:00 -0400

Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon recurrence

New prospective analyses confirm sustained disease-free survival (DFS) benefit with adjuvant Libtayo, including in patients who are minimal residual disease (MRD) negative at baseline

The late-breaking data were presented during a rapid oral session at the European Society for Medical Oncology (ESMO) 2026 Meeting

TARRYTOWN, N.Y., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Sun, 25 Oct 2026 05:15:00 -0400

New prospective analyses confirm sustained disease-free survival (DFS) benefit with adjuvant Libtayo, including in patients who are minimal residual disease (MRD) negative at baseline

The late-breaking data were presented during a rapid oral session at the European Society for Medical Oncology (ESMO) 2026 Meeting

TARRYTOWN, N.Y., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today

Regeneron Pharma (REGN) PT Raised to $980 at TD Cowen

Wed, 21 Oct 2026 08:12:29 -0400

TD Cowen analyst Tyler Van Buren raised the price target on Regeneron Pharma (NASDAQ: REGN) to $980.00 (from $960.00) while maintaining a Buy rating.

Regeneron Pharma (REGN) PT Raised to $865 at Piper Sandler

Mon, 19 Oct 2026 07:13:55 -0400

Piper Sandler analyst Biren Amin raised the price target on Regeneron Pharma (NASDAQ: REGN) to $865.00 (from $854.00) while maintaining a Overweight rating.

EU panel backs updated Libtayo dosing schedule for all cancer types

Fri, 16 Oct 2026 07:00:12 -0400

Regeneron Pharmaceuticals (NASDAQ: REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of an alternative dosing schedule for Libtayo (cemiplimab) across all of its approved indications in the European Union.

The recommended regimen would allow patients to receive Libtayo at 350 mg every three weeks for the first 12 weeks, followed by a higher dose of 700 mg every six weeks, each administered as a 30-minute intravenous infusion. The CHMP also recommended an option to shorten infusion time for the 350 mg dose to between 15 and 30

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Fri, 16 Oct 2026 07:00:00 -0400

Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment

Optional reduction of infusion time for 350 mg dose to 15 to 30 minutes, after a well-tolerated first dose over 30 minutes, also recommended by CHMP

TARRYTOWN, N.Y., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of an alternative dosing schedule for Libtayo^® (cemiplimab) across all approved indications.

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types

Fri, 16 Oct 2026 07:00:00 -0400

Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment

Optional reduction of infusion time for 350 mg dose to 15 to 30 minutes, after a well-tolerated first dose over 30 minutes, also recommended by CHMP

Form 4 REGENERON PHARMACEUTICAL For: Oct 13 Filed by: MURPHY ANDREW J

Thu, 15 Oct 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20261015/27193293.html

Form 144 REGENERON PHARMACEUTICAL Filed by: MURPHY ANDREW J

Wed, 14 Oct 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20261014/27187090.html

Regeneron's Pasatru shows no new bone lesions at 84 weeks in FOP trial

Mon, 12 Oct 2026 12:07:40 -0400

Regeneron Pharmaceuticals (NASDAQ: REGN) announced 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder that causes abnormal bone growth in soft tissue.

The data, presented at the American Society for Bone and Mineral Research Annual Meeting, showed that between weeks 56 and 84, no new heterotopic ossification (HO) lesions were detected in patients receiving Pasatru, compared with nine new lesions in the placebo group, as measured by CT scan. One lesion previously detected at week 56 in patients receiving the 3 mg/kg dose was no longer detectable at

Regeneron's Pasatru shows no new bone lesions at 84 weeks in FOP trial

Mon, 12 Oct 2026 12:07:40 -0400

Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

Mon, 12 Oct 2026 12:06:00 -0400

Pasatru is the first and only FDA-approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with FOP

Late-breaking data presented at ASBMR show sustained efficacy of Pasatru and a consistent safety profile from weeks 56 to 84, supporting long-term disease control

TARRYTOWN, N.Y., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive 84-week results from the Phase 3 OPTIMA trial evaluating Pasatru™ (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP). These longer-term findings for Pasatru demonstrated sustained efficacy

Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension

Mon, 12 Oct 2026 12:06:00 -0400

Late-breaking data presented at ASBMR show sustained efficacy of Pasatru and a consistent safety profile from weeks 56 to 84, supporting long-term disease control

Regeneron Pharma (REGN) PT Raised to $810 at RBC Capital

Thu, 08 Oct 2026 08:26:39 -0400

RBC Capital analyst Brian Abrahams raised the price target on Regeneron Pharma (NASDAQ: REGN) to $810.00 (from $737.00) while maintaining a Sector Perform rating.

Raymond James maintains Outperform rating on Regeneron with $911 target

Thu, 08 Oct 2026 05:20:39 -0400

Raymond James analyst Chris Raymond reiterated an Outperform rating and a $911.00 price target on Regeneron Pharmaceuticals (NASDAQ: REGN).

Raymond noted that Eylea trends remain stagnant, with a survey conducted by Spherix Global Insights in August 2026 of 100 respondents indicating that Eylea HD's neovascular age-related macular degeneration patient share declined quarter-over-quarter, from 18.9% to 16.1%.

The analyst stated that the absence of a pre-filled syringe format for Eylea HD is a significant drag on its use, adding that perceptions of efficacy for Eylea HD and competitor Vabysmo are essentially identical. Raymond said the franchise is likely to show limited growth until

Regeneron Pharma (REGN) PT Raised to $779 at Morgan Stanley

Wed, 07 Oct 2026 07:59:11 -0400

Morgan Stanley analyst Matthew Harrison raised the price target on Regeneron Pharma (NASDAQ: REGN) to $779.00 (from $758.00) while maintaining a Equalweight rating.

Regeneron Pharma (REGN) PT Raised to $780 at Truist Securities

Wed, 07 Oct 2026 07:14:30 -0400

Truist Securities analyst Greg Renza raised the price target on Regeneron Pharma (NASDAQ: REGN) to $780.00 (from $772.00) while maintaining a Buy rating.